Semaglutide Injection Sites & Administration Guide

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is administered via subcutaneous injection once weekly to specific body sites including the abdomen, outer thigh, or upper arm. Proper technique and site rotation are critical for consistent medication delivery and patient comfort during long-term treatment.

Understanding injection mechanics matters because individual factors—including genetic predispositions in GLP-1 receptor pathways—may influence how your body responds to the medication. At PlexusDx, we emphasize the importance of working with a qualified provider to establish a personalized administration plan aligned with your clinical picture.

Approved Injection Sites and Anatomical Considerations

The FDA-approved subcutaneous injection sites for semaglutide include the abdomen (at least 2 inches from the navel), outer thigh, and upper arm. Each site offers adequate subcutaneous tissue depth to ensure the medication reaches the intended tissue layer rather than entering muscle or vein.

Site selection may be influenced by patient comfort, skin condition, and accessibility. Rotating injection sites weekly helps reduce lipohypertrophy (localized fat thickening) and maintains consistent absorption rates. Your provider should confirm which sites are appropriate for your individual anatomy and skin integrity.

Injection Technique, Needle Depth, and Administration Variables

Proper semaglutide injection technique involves pinching the skin fold, inserting the needle at a 45-90 degree angle, and holding steady for 3-6 seconds before withdrawal. The standard needle gauge and depth are calibrated to deliver medication into subcutaneous tissue without reaching muscle.

Administration Element	Clinical Guidance
Injection Angle	45–90 degrees to skin surface for consistent subcutaneous delivery
Needle Insertion Time	Hold needle in place 3–6 seconds after full depression of plunger
Site Rotation Pattern	Change site each week; avoid injecting within 1 inch of previous injection
Subcutaneous Tissue Depth	Minimum 1/4 inch (6mm) recommended; varies by site and individual body composition
Needle Gauge Standard	29–31 gauge; smaller gauges minimize tissue trauma and discomfort
Timing in Weekly Cycle	Consistent day and time each week supports medication levels and side effect management

Site Rotation Strategies to Minimize Local Tissue Response

Rotating injection sites weekly prevents lipohypertrophy—a thickening of subcutaneous fat that can reduce medication absorption and create cosmetic concerns. A systematic rotation schedule (e.g., abdomen Week 1, left thigh Week 2, right thigh Week 3, upper arm Week 4) distributes injection trauma evenly.

Some patients experience mild bruising, redness, or induration at injection sites. These typically resolve within days. If you notice persistent swelling, warmth, or signs of infection at any site, contact your healthcare provider immediately. Proper rotation and aseptic technique significantly reduce these risks.

Safety, Tolerance, and When to Seek Provider Guidance

Before starting semaglutide, your provider should review your medical history, current medications, and any contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Injection site technique is important, but clinical eligibility and ongoing monitoring are equally critical.

Individual tolerance to semaglutide varies. Some patients experience mild nausea, appetite changes, or gastrointestinal effects independent of injection technique. Genetic factors in GLP-1 receptor signaling pathways may influence how your body tolerates the medication. Your provider should assess your response at each dose adjustment and remain available to address any concerns about administration or side effects.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test can help provide context about your genetic predispositions in the GLP1R gene and related peptide signaling pathways. Understanding these predispositions may support a more informed conversation with your provider about what to expect from semaglutide therapy and how your body may respond.

The test examines variants such as GLP1R rs6923761 and GIPR rs1800437, which relate to baseline GLP-1 receptor function and glucose regulation. These insights do not predict exact medication response or guarantee outcomes; rather, they may help explain individual variability in GLP-1 medication tolerance and efficacy.

When you combine knowledge of injection technique with awareness of your genetic predispositions in peptide pathways, you and your provider can make a more personalized treatment plan. This precision-wellness approach helps ensure that your semaglutide administration strategy aligns with your individual biology and clinical goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most affordable GLP-1 option for semaglutide injection sites & administra?

PlexusDx offers compounded semaglutide starting at $149/mo and a Microdose GLP-1 Protocol from $129/month — both from licensed 503A compounding pharmacies, with no membership fee.

Does PlexusDx serve patients in all 50 states?

Yes. PlexusDx serves all 50 states. Five states require a scheduled live video consultation before the first prescription is issued; all others use async intake.

How does genetic testing improve GLP-1 outcomes?

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide. PlexusDx's Precision Peptide Genetic Test evaluates 150+ relevant variants to guide medication selection.

Is compounded semaglutide the same as Wegovy or Ozempic?

Compounded semaglutide uses the same active ingredient but is not FDA-approved. It is prepared under federal compounding regulations at licensed 503A compounding pharmacies.

Can I use HSA or FSA funds to pay for PlexusDx?

Yes. Prescription GLP-1 medications from PlexusDx are HSA/FSA eligible with a valid prescription. PlexusDx accepts HSA and FSA cards directly at checkout.